Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C19H21NO4.ClH |
Molecular Weight | 363.835 |
Optical Activity | ( - ) |
Defined Stereocenters | 4 / 4 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.OC1=C2O[C@H]3C(=O)CC[C@@]4(O)[C@H]5CC(C=C1)=C2[C@@]34CCN5CC=C
InChI
InChIKey=RGPDIGOSVORSAK-STHHAXOLSA-N
InChI=1S/C19H21NO4.ClH/c1-2-8-20-9-7-18-15-11-3-4-12(21)16(15)24-17(18)13(22)5-6-19(18,23)14(20)10-11;/h2-4,14,17,21,23H,1,5-10H2;1H/t14-,17+,18+,19-;/m1./s1
Molecular Formula | C19H21NO4 |
Molecular Weight | 327.3743 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 4 / 4 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Molecular Formula | ClH |
Molecular Weight | 36.461 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Naloxone, sold under the brand name Narcan among others, is a medication used to block the effects of opioids, especially in overdose. Naloxone has an extremely high affinity for μ-opioid receptors in the central nervous system (CNS). Naloxone is a μ-opioid receptor (MOR) inverse agonist, and its rapid blockade of those receptors often produces rapid onset of withdrawal symptoms. Naloxone also has an antagonist action, though with a lower affinity, at κ- (KOR) and δ-opioid receptors (DOR). If administered in the absence of concomitant opioid use, no functional pharmacological activity occurs (except the inability for the body to combat pain naturally). In contrast to direct opiate agonists, which elicit opiate withdrawal symptoms when discontinued in opiate-tolerant people, no evidence indicates the development of tolerance or dependence on naloxone. The mechanism of action is not completely understood, but studies suggest it functions to produce withdrawal symptoms by competing for opiate receptor sites within the CNS (a competitive antagonist, not a direct agonist), thereby preventing the action of both endogenous and xenobiotic opiates on these receptors without directly producing any effects itself. When administered parenterally (e.g. intravenously or by injection), as is most common, naloxone has a rapid distribution throughout the body. The mean serum half-life has been shown to range from 30 to 81 minutes, shorter than the average half-life of some opiates, necessitating repeat dosing if opioid receptors must be stopped from triggering for an extended period. Naloxone is primarily metabolized by the liver. Its major metabolite is naloxone-3-glucuronide, which is excreted in the urine. Naloxone is useful both in acute opioid overdose and in reducing respiratory or mental depression due to opioids. Whether it is useful in those in cardiac arrest due to an opioid overdose is unclear. Naloxone is poorly absorbed when taken by mouth, so it is commonly combined with a number of oral opioid preparations, including buprenorphine and pentazocine, so that when taken orally, just the opioid has an effect, but if misused by injecting, the naloxone blocks the effect of the opioid. In a meta-analysis of people with shock, including septic, cardiogenic, hemorrhagic, or spinal shock, those who received naloxone had improved blood flow. Naloxone is also experimentally used in the treatment for congenital insensitivity to pain with anhidrosis, an extremely rare disorder (one in 125 million) that renders one unable to feel pain or differentiate temperatures. Naloxone can also be used as an antidote in overdose of clonidine, a medication that lowers blood pressure.
CNS Activity
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL233 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17149859 |
7.3 nM [IC50] | ||
Target ID: CHEMBL237 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12747782 |
49.8 nM [IC50] | ||
Target ID: CHEMBL236 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17388627 |
138.0 nM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | NARCAN Approved UsePentazocine Hydrochloride and Naloxone Hydrochloride Tablets, USP is indicated for the relief of moderate to severe pain. Pentazocine Hydrochloride and Naloxone Hydrochloride Tablets, USP is indicated for oral use only. Launch Date1971 |
|||
Primary | NARCAN Approved UsePentazocine Hydrochloride and Naloxone Hydrochloride Tablets, USP is indicated for the relief of moderate to severe pain. Pentazocine Hydrochloride and Naloxone Hydrochloride Tablets, USP is indicated for oral use only. Launch Date1971 |
|||
Primary | NARCAN Approved UsePentazocine Hydrochloride and Naloxone Hydrochloride Tablets, USP is indicated for the relief of moderate to severe pain. Pentazocine Hydrochloride and Naloxone Hydrochloride Tablets, USP is indicated for oral use only. Launch Date1971 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1.09 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/28444856/ |
10 mg/kg single, nasal dose: 10 mg/kg route of administration: Nasal experiment type: SINGLE co-administered: |
NALOXONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
4.83 ng/mL DRUG LABEL https://www.fda.gov/media/95283/download |
4 mg single, nasal dose: 4 mg route of administration: Nasal experiment type: SINGLE co-administered: |
NALOXONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
0.87 ng/mL DRUG LABEL https://www.fda.gov/media/95283/download |
0.4 mg single, intramuscular dose: 0.4 mg route of administration: Intramuscular experiment type: SINGLE co-administered: |
NALOXONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
9.62 ng/mL DRUG LABEL https://www.fda.gov/media/95283/download |
8 mg single, nasal dose: 8 mg route of administration: Nasal experiment type: SINGLE co-administered: |
NALOXONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
37.1 ng × min/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/28444856/ |
10 mg/kg single, nasal dose: 10 mg/kg route of administration: Nasal experiment type: SINGLE co-administered: |
NALOXONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
7.9 ng × h/mL DRUG LABEL https://www.fda.gov/media/95283/download |
4 mg single, nasal dose: 4 mg route of administration: Nasal experiment type: SINGLE co-administered: |
NALOXONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
1.68 ng × h/mL DRUG LABEL https://www.fda.gov/media/95283/download |
0.4 mg single, intramuscular dose: 0.4 mg route of administration: Intramuscular experiment type: SINGLE co-administered: |
NALOXONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
15 ng × h/mL DRUG LABEL https://www.fda.gov/media/95283/download |
8 mg single, nasal dose: 8 mg route of administration: Nasal experiment type: SINGLE co-administered: |
NALOXONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
28.2 min EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/28444856/ |
10 mg/kg single, nasal dose: 10 mg/kg route of administration: Nasal experiment type: SINGLE co-administered: |
NALOXONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
1.2 h DRUG LABEL https://www.fda.gov/media/95283/download |
0.4 mg single, intramuscular dose: 0.4 mg route of administration: Intramuscular experiment type: SINGLE co-administered: |
NALOXONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
2.1 h DRUG LABEL https://www.fda.gov/media/95283/download |
8 mg single, nasal dose: 8 mg route of administration: Nasal experiment type: SINGLE co-administered: |
NALOXONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
0.8 mg single, intramuscular Dose: 0.8 mg Route: intramuscular Route: single Dose: 0.8 mg Sources: |
healthy, 23.8 years (range: 22.6–25 years) Health Status: healthy Age Group: 23.8 years (range: 22.6–25 years) Sex: M+F Sources: |
|
160 mg/m2 single, intravenous Highest studied dose Dose: 160 mg/m2 Route: intravenous Route: single Dose: 160 mg/m2 Sources: |
unhealthy, 35-85 years |
Disc. AE: Hypotension, Bradycardia... Other AEs: Nausea, Emesis... AEs leading to discontinuation/dose reduction: Hypotension (3 patients) Other AEs:Bradycardia (2 patients) Myoclonus (1 patient) Hypertension (1 patient) Nausea (32%) Sources: Emesis (5%) Seizures (5%) Headache (5%) Confusion (5%) Agitation (3%) |
8 mg single, intranasal Dose: 8 mg Route: intranasal Route: single Dose: 8 mg Sources: |
healthy, adult Health Status: healthy Age Group: adult Sources: |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Hypertension | 1 patient Disc. AE |
160 mg/m2 single, intravenous Highest studied dose Dose: 160 mg/m2 Route: intravenous Route: single Dose: 160 mg/m2 Sources: |
unhealthy, 35-85 years |
Myoclonus | 1 patient Disc. AE |
160 mg/m2 single, intravenous Highest studied dose Dose: 160 mg/m2 Route: intravenous Route: single Dose: 160 mg/m2 Sources: |
unhealthy, 35-85 years |
Bradycardia | 2 patients Disc. AE |
160 mg/m2 single, intravenous Highest studied dose Dose: 160 mg/m2 Route: intravenous Route: single Dose: 160 mg/m2 Sources: |
unhealthy, 35-85 years |
Hypotension | 3 patients Disc. AE |
160 mg/m2 single, intravenous Highest studied dose Dose: 160 mg/m2 Route: intravenous Route: single Dose: 160 mg/m2 Sources: |
unhealthy, 35-85 years |
Agitation | 3% | 160 mg/m2 single, intravenous Highest studied dose Dose: 160 mg/m2 Route: intravenous Route: single Dose: 160 mg/m2 Sources: |
unhealthy, 35-85 years |
Nausea | 32% | 160 mg/m2 single, intravenous Highest studied dose Dose: 160 mg/m2 Route: intravenous Route: single Dose: 160 mg/m2 Sources: |
unhealthy, 35-85 years |
Confusion | 5% | 160 mg/m2 single, intravenous Highest studied dose Dose: 160 mg/m2 Route: intravenous Route: single Dose: 160 mg/m2 Sources: |
unhealthy, 35-85 years |
Emesis | 5% | 160 mg/m2 single, intravenous Highest studied dose Dose: 160 mg/m2 Route: intravenous Route: single Dose: 160 mg/m2 Sources: |
unhealthy, 35-85 years |
Headache | 5% | 160 mg/m2 single, intravenous Highest studied dose Dose: 160 mg/m2 Route: intravenous Route: single Dose: 160 mg/m2 Sources: |
unhealthy, 35-85 years |
Seizures | 5% | 160 mg/m2 single, intravenous Highest studied dose Dose: 160 mg/m2 Route: intravenous Route: single Dose: 160 mg/m2 Sources: |
unhealthy, 35-85 years |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://pubmed.ncbi.nlm.nih.gov/19874646/ Page: 7,8 |
likely | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/19874646/ Page: 7,8 |
no | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/19874646/ Page: 7,8 |
no | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/19874646/ Page: 7,8 |
no | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/19874646/ Page: 7,8 |
no | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/19874646/ Page: 7,8 |
no | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/19874646/ Page: 7,8 |
no | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/19874646/ Page: 7,8 |
no | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/19874646/ Page: 7,8 |
no | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/19874646/ Page: 7,8 |
no | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/19874646/ Page: 7,8 |
yes | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/19874646/ Page: 7,8 |
yes | |||
yes |
PubMed
Title | Date | PubMed |
---|---|---|
Changes in benzodiazepine-receptor activity modify morphine withdrawal syndrome in mice. | 1992 Aug |
|
The NMDA receptor antagonist MK-801 prevents long-lasting non-associative morphine tolerance in the rat. | 1992 Mar 20 |
|
Morphine preconditioning attenuates neutrophil activation in rat models of myocardial infarction. | 1998 Dec |
|
Neurotransmitter-mediated open-field behavioral action of CGRP. | 1999 |
|
Repressive/defensive coping, endogenous opioids and health: how a life so perfect can make you sick. | 1999 Jan 18 |
|
[The discriminative stimulus properties of naloxone during dissociative learning in a Y maze in morphine-dependent rats]. | 1999 Jan-Feb |
|
Modification of naloxone-induced withdrawal signs by dextromethorphan in morphine-dependent mice. | 1999 Jul 14 |
|
Methadone, ciprofloxacin, and adverse drug reactions. | 2000 Dec 16 |
|
Fentanyl-induced chest wall rigidity and laryngospasm in preterm and term infants. | 2000 Mar |
|
Effect of whole-body vibration in the vertical axis on cortisol and adrenocorticotropic hormone levels in piglets. | 2001 Apr |
|
Opioid-induced hyperalgesia and incisional pain. | 2001 Jul |
|
Inverse agonists and neutral antagonists at mu opioid receptor (MOR): possible role of basal receptor signaling in narcotic dependence. | 2001 Jun |
|
Morphine-induced dependence and sensitization are altered in mice deficient in AMPA-type glutamate receptor-A subunits. | 2001 Jun 15 |
|
Delta9-tetrahydrocannabinol releases and facilitates the effects of endogenous enkephalins: reduction in morphine withdrawal syndrome without change in rewarding effect. | 2001 May |
|
Delayed opioid withdrawal-like reaction in primary biliary cirrhosis following naloxone therapy. | 2001 Sep |
|
Effects of Ferula gummosa Boiss. fractions on morphine dependence in mice. | 2001 Sep |
|
Naloxone methiodide reverses opioid-induced respiratory depression and analgesia without withdrawal. | 2002 Jun 7 |
|
Identification of opioid-regulated genes in human lymphocytic cells by differential display: upregulation of Krüppel-like factor 7 by morphine. | 2003 Dec 10 |
|
Safety of enteral naloxone and i.v. neostigmine when used to relieve constipation. | 2003 Jun 15 |
|
Bovine lactoferrin has a nitric oxide-dependent hypotensive effect in rats. | 2004 Feb |
|
Magnesium influence on morphine--induced pharmacodependence in rats. | 2004 Mar |
|
Evaluation of fresh and cryopreserved hepatocytes as in vitro drug metabolism tools for the prediction of metabolic clearance. | 2004 Nov |
|
[Preclinical management of accidental methadone intoxication of a 4-year-old girl. Antagonist or intubation?]. | 2004 Oct |
|
Ventricular tachycardia following naloxone administration in an illicit drug misuse. | 2005 Aug |
|
Calcitonin gene-related peptide-induced suppression of luteinizing hormone pulses in the rat: the role of endogenous opioid peptides. | 2005 Aug 1 |
|
Effect of fentanyl on lidocaine-induced convulsions in mice. | 2005 Dec |
|
[Effect of naloxone on expression of Bcl-2 protein and tumor necrosis factor-alpha in rats with acute myocardial ischemia/reperfusion injury]. | 2005 Jul |
|
Prediction of genotoxicity of chemical compounds by statistical learning methods. | 2005 Jun |
|
Ultrafine particles cross cellular membranes by nonphagocytic mechanisms in lungs and in cultured cells. | 2005 Nov |
Sample Use Guides
Opioid Overdose–Known or Suspected: An initial dose of 0.4 mg to 2 mg of NARCAN may be administered intravenously. If the desired degree of counteraction and improvement in respiratory functions are not obtained, it may be repeated at two- to three-minute intervals. If no response is observed after 10 mg of NARCAN have been administered, the diagnosis of opioid-induced or partial opioid-induced toxicity should be questioned. Intramuscular or subcutaneous administration may be necessary if the intravenous route is not available.
Postoperative Opioid Depression: For the partial reversal of opioid depression following the use of opioids during surgery, smaller doses of NARCAN are usually sufficient. The dose of NARCAN should be titrated according to the patient’s response. For the initial reversal of respiratory depression, NARCAN should be injected in increments of 0.1 to 0.2 mg intravenously at two- to three-minute intervals to the desired degree of reversal, i.e., adequate ventilation and alertness without significant pain or discomfort. Larger than necessary dosage of NARCAN may result in significant reversal of analgesia and increase in blood pressure. Similarly, too rapid reversal may induce nausea, vomiting, sweating or circulatory stress.
Repeat doses of NARCAN may be required within one- to two-hour intervals depending upon the amount, type (i.e., short or long acting) and time interval since last administration of an opioid. Supplemental intramuscular doses have been shown to produce a longer lasting effect.
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/17624703
MDCKII-MDR1 assay. Stock solutions of Naloxone (20 mM) were prepared in 100% DMSO and then diluted to the final concentration of 10 mkM, in Dulbecco’s PBS. Naloxone were tested in both directions, apicalto-basolateral (A→B) and basolateral-to-apical (B→A), in duplicate. The ratio BA/AB >2 indicates an efflux phenomena. Permeability studies were conducted at 37 ◦C in incubator for 60 min. The monolayer integrity was evaluated by measuring the TransEpithelial Electrical Resistance (TEER) by using the Millicell-ERS system (Millipore Corporation) and it was considered integer if the resistancewas between 200 and 300 cm2. After the transport study the monolayer integrity was measured
in each well by adding a 0.02 mg/mL solution of lucifer yellow (LY); the test was conducted at 37 ◦C for 60 min, and the fluorescence (RFU) was measured at 485/535 nm.
Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 17:48:16 GMT 2025
by
admin
on
Mon Mar 31 17:48:16 GMT 2025
|
Record UNII |
F850569PQR
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Brand Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C681
Created by
admin on Mon Mar 31 17:48:16 GMT 2025 , Edited by admin on Mon Mar 31 17:48:16 GMT 2025
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
100000091649
Created by
admin on Mon Mar 31 17:48:16 GMT 2025 , Edited by admin on Mon Mar 31 17:48:16 GMT 2025
|
PRIMARY | |||
|
C678
Created by
admin on Mon Mar 31 17:48:16 GMT 2025 , Edited by admin on Mon Mar 31 17:48:16 GMT 2025
|
PRIMARY | |||
|
203192
Created by
admin on Mon Mar 31 17:48:16 GMT 2025 , Edited by admin on Mon Mar 31 17:48:16 GMT 2025
|
PRIMARY | RxNorm | ||
|
SUB03382MIG
Created by
admin on Mon Mar 31 17:48:16 GMT 2025 , Edited by admin on Mon Mar 31 17:48:16 GMT 2025
|
PRIMARY | |||
|
357-08-4
Created by
admin on Mon Mar 31 17:48:16 GMT 2025 , Edited by admin on Mon Mar 31 17:48:16 GMT 2025
|
PRIMARY | |||
|
DTXSID70957097
Created by
admin on Mon Mar 31 17:48:16 GMT 2025 , Edited by admin on Mon Mar 31 17:48:16 GMT 2025
|
PRIMARY | |||
|
F850569PQR
Created by
admin on Mon Mar 31 17:48:16 GMT 2025 , Edited by admin on Mon Mar 31 17:48:16 GMT 2025
|
PRIMARY | |||
|
757109
Created by
admin on Mon Mar 31 17:48:16 GMT 2025 , Edited by admin on Mon Mar 31 17:48:16 GMT 2025
|
PRIMARY | |||
|
DBSALT000126
Created by
admin on Mon Mar 31 17:48:16 GMT 2025 , Edited by admin on Mon Mar 31 17:48:16 GMT 2025
|
PRIMARY | |||
|
206-611-0
Created by
admin on Mon Mar 31 17:48:16 GMT 2025 , Edited by admin on Mon Mar 31 17:48:16 GMT 2025
|
PRIMARY | |||
|
m7717
Created by
admin on Mon Mar 31 17:48:16 GMT 2025 , Edited by admin on Mon Mar 31 17:48:16 GMT 2025
|
PRIMARY | Merck Index | ||
|
CHEMBL80
Created by
admin on Mon Mar 31 17:48:16 GMT 2025 , Edited by admin on Mon Mar 31 17:48:16 GMT 2025
|
PRIMARY | |||
|
5464092
Created by
admin on Mon Mar 31 17:48:16 GMT 2025 , Edited by admin on Mon Mar 31 17:48:16 GMT 2025
|
PRIMARY | |||
|
31892
Created by
admin on Mon Mar 31 17:48:16 GMT 2025 , Edited by admin on Mon Mar 31 17:48:16 GMT 2025
|
PRIMARY | |||
|
NALOXONE HYDROCHLORIDE
Created by
admin on Mon Mar 31 17:48:16 GMT 2025 , Edited by admin on Mon Mar 31 17:48:16 GMT 2025
|
PRIMARY | Description: A white or almost white powder. Solubility: Soluble in water; slightly soluble in ethanol (~750 g/l) TS; practically insoluble in ether R.Category: Narcotic antagonist. Storage: Naloxone hydrochloride should be kept in a tightly closed container, protected from light. Labelling: The designation on the container of Naloxone hydrochloride should state whether the substance is in the anhydrousform or is the dihydrate. Additional information: Even in the absence of light, Naloxone hydrochloride is gradually degraded on exposure to a humidatmosphere, the decomposition being faster at higher temperatures. It melts at about 177?C. Definition: Naloxone hydrochloride contains not less than 98.0% and not more than 102.0% of C19H21NO4,HCl, calculated withreference to the dried substance. | ||
|
SUB25206
Created by
admin on Mon Mar 31 17:48:16 GMT 2025 , Edited by admin on Mon Mar 31 17:48:16 GMT 2025
|
PRIMARY | |||
|
F850569PQR
Created by
admin on Mon Mar 31 17:48:16 GMT 2025 , Edited by admin on Mon Mar 31 17:48:16 GMT 2025
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SOLVATE->ANHYDROUS |
|
||
|
PARENT -> SALT/SOLVATE |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|